123 results on '"Moots RJ"'
Search Results
2. Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: results of the TRACTISS randomised double-blind multicentre substudy
- Author
-
Fisher, BA, Everett, CC, Rout, J, O'Dwyer, JL, Emery, P, Pitzalis, C, Ng, W-F, Carr, A, Pease, CT, Price, EJ, Sutcliffe, N, Makdissi, J, Tappuni, AR, Gendi, NST, Hall, FC, Ruddock, SP, Fernandez, C, Hulme, CT, Davies, KA, Edwards, CJ, Lanyon, PC, Moots, RJ, Roussou, E, Richards, A, Sharples, LD, Bombardieri, M, and Bowman, SJ
- Subjects
Adult ,Male ,B cells ,Clinical and Epidemiological Research ,Middle Aged ,R1 ,Salivary Glands ,Sjogren's Syndrome ,Treatment Outcome ,sjøgren’s syndrome ,Double-Blind Method ,Humans ,Immunologic Factors ,Female ,Rituximab ,Aged ,Ultrasonography - Abstract
Objectives To compare the effects of rituximab versus placebo on salivary gland ultrasound (SGUS) in primary Sjögren’s syndrome (PSS) in a multicentre, multiobserver phase III trial substudy.\ud \ud \ud \ud Methods Subjects consenting to SGUS were randomised to rituximab or placebo given at weeks 0, 2, 24 and 26, and scanned at baseline and weeks 16 and 48. Sonographers completed a 0–11 total ultrasound score (TUS) comprising domains of echogenicity, homogeneity, glandular definition, glands involved and hypoechoic foci size. Baseline-adjusted TUS values were analysed over time, modelling change from baseline at each time point. For each TUS domain, we fitted a repeated-measures logistic regression model to model the odds of a response in the rituximab arm (≥1-point improvement) as a function of the baseline score, age category, disease duration and time point.\ud \ud \ud \ud Results 52 patients (n=26 rituximab and n=26 placebo) from nine centres completed baseline and one or more follow-up visits. Estimated between-group differences (rituximab-placebo) in baseline-adjusted TUS were −1.2 (95% CI −2.1 to −0.3; P=0.0099) and −1.2 (95% CI −2.0 to −0.5; P=0.0023) at weeks 16 and 48. Glandular definition improved in the rituximab arm with an OR of 6.8 (95% CI 1.1 to 43.0; P=0.043) at week 16 and 10.3 (95% CI 1.0 to 105.9; P=0.050) at week 48.\ud \ud \ud \ud Conclusions We demonstrated statistically significant improvement in TUS after rituximab compared with placebo. This encourages further research into both B cell depletion therapies in PSS and SGUS as an imaging biomarker. \ud \ud Trial registration number 65360827, 2010-021430-64; Results.
- Published
- 2018
3. Randomized Controlled Trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's Syndrome
- Author
-
Bowman, SJ, Everett, CC, O'Dwyer, JL, Emery, P, Pitzalis, C, Ng, WF, Pease, CT, Price, EJ, Sutcliffe, N, St Gendi, N, Hall, FC, Ruddock, SP, Fernandez, C, Reynolds, C, Hulme, CT, Davies, KA, Edwards, CJ, Lanyon, PC, Moots, RJ, Roussou, E, Giles, IP, Sharples, LD, and Bombardieri, M
- Abstract
We investigated whether rituximab, an anti-B-cell therapy, improved symptoms of fatigue and oral dryness in patients with Primary Sjögren's Syndrome (PSS). : Multicentre, randomised, double-blind, parallel-group placebo-controlled trial, including Health Economic Analysis. Anti-Ro positive patients with PSS, symptomatic fatigue and oral dryness were recruited from 25 UK rheumatology clinics from August 2011 to January 2014. Patients were centrally-randomised to either placebo IV or rituximab IV (1000mg in 250mL) at weeks 0, 2, 24 and 26, with pre-and post-infusion medication including corticosteroids. Primary endpoint was the proportion of patients achieving 30% reduction in either fatigue or oral dryness at 48 weeks, measured by Visual Analogue Scale. Other outcomes included salivary and lachrymal flow rates, quality of life, ESSDAI and ESSPRI, symptoms of ocular and overall dryness, pain, global disease assessment and cost-effectiveness. ISRCTN 65360827 Results: All patients (n=133) randomised to placebo (n=66) and to rituximab (n=67) were included in the primary analysis. Among complete cases, 21/56 placebo and 24/61 rituximab patients achieved primary endpoint. After multiple imputation of missing outcomes, placebo and rituximab response rates were 36·8% and 39·8%, respectively (adjusted odds ratio 1·13 95% CI 0·50-2·55). There were no significant improvements in any outcome measure, except unstimulated salivary flow. Mean (SD) costs for rituximab and placebo were £10,752 (SD 264·75) and £2,672 (SD 241·71). There were slightly more adverse events reported in total for rituximab, but no difference in serious adverse events (ten in each group). : Rituximab is neither clinically or cost-effective in this patient population. This article is protected by copyright. All rights reserved.
- Published
- 2017
4. VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis
- Author
-
Bacon, PA, Moots, RJ, Exley, A, Luqmani, R, and Rasmussen, N
- Published
- 2016
5. Vasculitis integrated total assessment log (VITAL): A system for clinical evaluation of vasculitis
- Author
-
Luqmani, RA, Talbot, H, Lamb, A, Armstrong, C, Kitas, GD, Exley, A, Moots, RJ, and Bacon, PA
- Published
- 2016
6. Prediction of Remission and Low Disease Activity in DMARD-Refractory Patients with RA Treated with Golimumab
- Author
-
Vastesaeger, N, Durez, P, Dasgupta, B, Combe, B, Schulze-Koops, H, Louw, I, Wollenhaupt, J, Zerbini, C, Beaulieu, A, Pavelka, K, Lazaro, M, Garcia Kutzbach, A, Moots, RJ, Amital, H, Huyck, S, Fu, B, Govoni, M, Vastesaeger, N, Durez, P, Dasgupta, B, Combe, B, Schulze-Koops, H, Louw, I, Wollenhaupt, J, Zerbini, C, Beaulieu, A, Pavelka, K, Lazaro, M, Garcia Kutzbach, A, Moots, RJ, Amital, H, Huyck, S, Fu, B, and Govoni, M
- Published
- 2015
7. Quality indicators in rheumatoid arthritis: results from the METEOR database
- Author
-
Navarro Compán, V, Smolen, J, Huizinga, Twj, Landewé, R, Ferraccioli, Gianfranco, Da Silva, Jap, Moots, Rj, Kay, J, Van Der Heijde, D., Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), Navarro Compán, V, Smolen, J, Huizinga, Twj, Landewé, R, Ferraccioli, Gianfranco, Da Silva, Jap, Moots, Rj, Kay, J, Van Der Heijde, D., and Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428)
- Abstract
To test the feasibility of collecting, storing, retrieving and analysing necessary information to fulfil a preliminary set of quality indicators (QIs) that have been proposed by an international task force in a large multinational clinical practice database of patients with RA.
- Published
- 2015
8. Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database
- Author
-
Gvozdenović, E, Wolterbeek, R, Allaart, Cf, Brenol, C, Dougados, M, Emery, P, Ferraccioli, Gianfranco, Van Der Heijde, D, Huizinga, Tw, Kay, J, Martin Mola, E, Moots, Rj, Da Silva, Jap, Smolen, J, Veale, D, Landewé, Rb, Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), Gvozdenović, E, Wolterbeek, R, Allaart, Cf, Brenol, C, Dougados, M, Emery, P, Ferraccioli, Gianfranco, Van Der Heijde, D, Huizinga, Tw, Kay, J, Martin Mola, E, Moots, Rj, Da Silva, Jap, Smolen, J, Veale, D, Landewé, Rb, and Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428)
- Abstract
The aim of the study was to compare the differences between patient global disease activity (PtGDA) and physician global disease activity (PhGDA) score within and across 13 countries in the METEOR (Measurement of Efficacy of Treatment in the "Era of Outcome" in Rheumatology) database.
- Published
- 2015
9. Synovial fluid neutrophils transcribe and express class II major histocompatibility complex molecules in rheumatoid arthritis
- Author
-
Cross, A, Bucknall, Rc, Cassatella, Marco Antonio, Edward, Sw, and Moots, Rj
- Published
- 2003
10. The Michael Mason Prize Essay 1998. A fistful of T cells.
- Author
-
Moots, RJ
- Abstract
Evidence incriminating T cells in rheumatoid arthritis (RA) is strong but circumstantial - like a smoking gun at the scene of a crime. To investigate this, T lymphocytes were studied in health and disease. The effects of mutations in the groove of HLA-A2 on peptide presentation to T cells was studied to investigate normal T cell function. This allowed a detailed description of the interaction between individual MHC residues and antigens. Subsequently, T cells in the autoimmune disease, multiple sclerosis, were studied, to investigate the mechanisms for breakdown in peripheral tolerance. T-cell clones that recognized both autoantigens and viral proteins were isolated, suggesting that infection may trigger disease. Autoantigens would need to be defined to use this strategy in RA. T-cell responses to type II collagen, a candidate auto-antigen, were therefore studied in RA and an epitope successfully defined. The search for microbial 'mimics' triggering RA, and novel forms of immunotherapy are now possible - with potential rehabilitation of T cells. [ABSTRACT FROM PUBLISHER]
- Published
- 1998
- Full Text
- View/download PDF
11. Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis.
- Author
-
Taylor PC, Downie B, Han L, Hawtin R, Hertz A, Moots RJ, and Takeuchi T
- Abstract
Introduction: High baseline neutrophil-to-lymphocyte ratio (NLR) in rheumatoid arthritis (RA) has been associated with positive responses to biologic tumor necrosis factor inhibition and negative responses to conventional synthetic disease-modifying antirheumatic drug (csDMARD) triple therapy. Datasets from three randomized clinical trials in patients with RA were used to test the hypothesis that baseline NLR is associated with improved clinical response to filgotinib in methotrexate (MTX)-naïve or MTX-experienced RA populations., Methods: Patients from FINCH 1 (inadequate response to MTX, MTX-IR; NCT02889796), FINCH 2 (inadequate response to biologic DMARDs; NCT02873936), and FINCH 3 (MTX-naïve; NCT02886728) were classified as baseline NLR-High or baseline NLR-Low based on a previously published cut point of 2.7. In total, 3365 patients were included across the three studies. Differences in clinical outcomes and patient-reported outcomes (PROs) were determined using linear-regression models., Results: Control-arm patients (placebo + MTX/placebo + csDMARD) classified as NLR-High exhibited worse continuous clinical and PRO responses at week 12 across clinical trials compared to NLR-Low patients. In contrast, NLR-High patients who received FIL 200 mg + MTX/csDMARD exhibited consistently better responses after 12 weeks compared to NLR-Low patients across clinical trials, clinical endpoints, and PROs. These trends were most prominent among the MTX-IR population., Conclusion: The 2.7 baseline NLR cut point could be used to enrich for patients most likely to benefit from the addition of filgotinib to background MTX/csDMARD. Use of baseline NLR as part of therapeutic decision-making would not require additional diagnostics and could contribute to improved outcomes for patients with RA., Trial Registration: Clinicaltrials.gov: NCT02889796; NCT02873936; NCT02886728., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
12. Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence.
- Author
-
Cross AL, Hawkes J, Frankland H, Mediana A, Wright HL, Goodson NJ, Edwards SW, and Moots RJ
- Subjects
- Humans, Neutrophils, Interleukin-17, Antibodies, Monoclonal therapeutic use, Treatment Outcome, Arthritis, Psoriatic drug therapy, Arthritis, Psoriatic chemically induced, Psoriasis drug therapy
- Abstract
Objectives: Identifying that dysfunction of the IL-23/17 axis underlies PsA has led to the development of effective targeted therapies such as the IL-17A inhibitor secukinumab. As IL-17A stimulates the secretion of neutrophil chemoattractants, such as CXCL8 (IL-8), we examined the effect of secukinumab on neutrophil function in PsA., Methods: Nineteen patients with active PsA were treated with secukinumab. Clinical response [PsA Response Criteria (PsARC) and Psoriasis Area and Severity Index (PASI)] and peripheral blood neutrophil function (apoptosis, receptor expression, phagocytosis/killing, chemotaxis and RNA expression) were measured at 12 week intervals for 48 weeks and compared with age- and sex-matched healthy controls., Results: At 12 weeks, 12/16 (75%) patients had a PsARC response (100% at 36 weeks) and 10/14 (71%) achieved a 90% PASI response. At baseline, there were no differences in PsA neutrophil reactive oxygen species generation, constitutive or cytokine-delayed apoptosis, chemotaxis or phagocytosis of opsonized Staphylococcus aureus compared with healthy controls. Similarly, there were no differences in these functions from baseline to 12 weeks of therapy. However, surface levels of CD11b/CD18 and CD63 increased and expression of CD16 decreased during therapy. In addition, in a subgroup of early (12 week) responders to secukinumab, RNA sequencing revealed transcriptome changes predicting down-regulation of cytokine signalling and chemotaxis pathways and up-regulation of de novo gene expression pathways, including translation initiation, mRNA catabolism and translation., Conclusion: Complex changes in the properties of circulating neutrophils occur with secukinumab treatment in PsA that may indicate altered responsiveness to changes in both local and systemic levels of pro-inflammatory cytokines. However, host defence processes of neutrophils were unaltered., (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
13. The challenge of ocular inflammation in systemic vasculitis: How to address inequalities of care?
- Author
-
Ghadiri N, Nair J, and Moots RJ
- Abstract
Competing Interests: Conflict of Interest Robert J Moots is a Co-Editor-in-Chief of the journal. The article was subject to the journal's standard procedures, with peer review handled independently of the editor.
- Published
- 2023
- Full Text
- View/download PDF
14. Metabolic Profiling of Rheumatoid Arthritis Neutrophils Reveals Altered Energy Metabolism That Is Not Affected by JAK Inhibition.
- Author
-
Chokesuwattanaskul S, Fresneda Alarcon M, Mangalakumaran S, Grosman R, Cross AL, Chapman EA, Mason D, Moots RJ, Phelan MM, and Wright HL
- Abstract
Neutrophils play a key role in the pathophysiology of rheumatoid arthritis (RA) where release of ROS and proteases directly causes damage to joints and tissues. Neutrophil function can be modulated by Janus Kinase (JAK) inhibitor drugs, including tofacitinib and baricitinib, which are clinically effective treatments for RA. However, clinical trials have reported increased infection rates and transient neutropenia during therapy. The subtle differences in the mode of action, efficacy and safety of JAK inhibitors have been the primary research topic of many clinical trials and systematic reviews, to provide a more precise and targeted treatment to patients. The aim of this study was to determine both the differences in the metabolome of neutrophils from healthy controls and people with RA, and the effect of different JAK inhibitors on the metabolome of healthy and RA neutrophils. Isolated neutrophils from healthy controls (HC) (n = 6) and people with RA (n = 7) were incubated with baricitinib, tofacitinib or a pan-JAK inhibitor (all 200 ng/mL) for 2 h. Metabolites were extracted, and 1H nuclear magnetic resonance (NMR) was applied to study the metabolic changes. Multivariate analyses and machine learning models showed a divergent metabolic pattern in RA neutrophils compared to HC at 0 h (F1 score = 86.7%) driven by energy metabolites (ATP, ADP, GTP and glucose). No difference was observed in the neutrophil metabolome when treated with JAK inhibitors. However, JAK inhibitors significantly inhibited ROS production and baricitinib decreased NET production (p < 0.05). Bacterial killing was not impaired by JAK inhibitors, indicating that the effect of JAK inhibitors on neutrophils can inhibit joint damage in RA without impairing host defence. This study highlights altered energy metabolism in RA neutrophils which may explain the cause of their dysregulation in inflammatory disease.
- Published
- 2022
- Full Text
- View/download PDF
15. The association between increased body mass index and response to conventional synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: results from the METEOR database.
- Author
-
Dey M, Zhao SS, Moots RJ, Bergstra SA, Landewe RB, and Goodson NJ
- Subjects
- Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid complications, Databases as Topic, Female, Humans, Linear Models, Logistic Models, Male, Methotrexate administration & dosage, Middle Aged, Obesity complications, Patient Acuity, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Body Mass Index, Methotrexate therapeutic use
- Abstract
Background: Few data exist on the association between increased BMI and response to conventional synthetic DMARDs (csDMARDs) in RA. We aimed to explore the association between increased (overweight or obese) BMI on csDMARD prescribing, MTX dose and disease activity over 12 months., Methods: Participants in an international RA database were stratified into early (<1 year post-diagnosis) and established RA. EULAR response, 28-joint DAS (DAS28) remission and treatments were recorded at baseline, 6 months and 12 months. Increased BMI was explored in early and established RA as predictors of good EULAR response, DAS28 remission, number of csDMARDs and MTX dose, using logistic and linear regression., Results: Data from 1313 patients, 44.3% with early RA, were examined. In early RA, increased BMI was not significantly associated with remission. In established RA, obese patients on monotherapy were significantly less likely to achieve good EULAR response or DAS28 remission at 6 months and more likely to be treated with combination csDMARDs compared with normal BMI. In patients taking MTX, overweight and obese patients with early and established RA were exposed to higher MTX doses (mono- and combination therapy), with a mean dose of 20 mg/week, compared with 15 mg/week in those of normal BMI., Conclusion: We observed that compared with patients with normal BMI, overweight and obese individuals experienced more intensive csDMARD exposures. Similar response rates were observed in early RA but increased BMI was associated with reduced response in established RA. Optimization of targeted RA treatment remains important, particularly in those with increased BMI where response in established disease may be attenuated., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
16. Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis.
- Author
-
Zhao SS, Jones GT, Hughes DM, Moots RJ, and Goodson NJ
- Subjects
- Anxiety physiopathology, Anxiety prevention & control, Axial Spondyloarthritis complications, Cognition physiology, Cross-Sectional Studies, Depression physiopathology, Depression prevention & control, Educational Status, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome, Anxiety complications, Axial Spondyloarthritis drug therapy, Cognition drug effects, Depression complications, Mental Health, Tumor Necrosis Factor Inhibitors therapeutic use
- Abstract
Objectives: Depression and anxiety are associated with more severe disease in cross-sectional studies of axial spondyloarthritis (axSpA). We examined the association between baseline symptoms of depression or anxiety and response to TNF inhibitors (TNFi) in axSpA., Methods: Biologic naïve participants from a national axSpA register completed the Hospital Anxiety and Depression Scale (HADS) before initiating TNFi. Symptoms of anxiety and depression were each categorized as moderate-severe (≥11), mild (8-10) and 'none' (≤7), and compared against change in disease indices [BASDAI and AS Disease Activity Score (ASDAS)] over time and time to treatment discontinuation using marginal structural models. Inverse-probability weights balanced baseline age, gender, BMI, deprivation, education and baseline values of respective disease indices., Results: Of the 742 participants (67% male, mean age 45 years), 176 (24%) had moderate-severe and 26% mild depression; 295 (40%) had moderate-severe and 23% mild anxiety. Baseline disease activity was higher in higher HADS symptom categories for both depression and anxiety. Participants with moderate-severe depression had significantly poorer response compared with those with 'none' throughout follow-up. At 6 months, the difference was approximately 2.2 BASDAI and 0.8 ASDAS units after balancing their baseline values. Equivalent comparisons for anxiety were 1.7 BASDAI and 0.7 ASDAS units. Treatment discontinuation was 1.59-fold higher (hazard ratio 95% CI: 1.12, 2.26) in participants with moderate-severe anxiety compared with 'none'., Conclusions: Symptoms of depression and anxiety at TNFi initiation are associated with poorer treatment outcomes. Targeted interventions to optimize mental health have potential to substantially improve treatment response and persistence., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2021
- Full Text
- View/download PDF
17. Isolation of Microvesicles from Human Circulating Neutrophils.
- Author
-
Zhan D, McConachie E, Edwards SW, Wright HL, Moots RJ, and Honsawek S
- Abstract
Neutrophil-derived microvesicles (NDMVs) are liberated by neutrophils upon cell activation by molecules. Once activated, neutrophils are primarily involved in acute inflammation; however, the microvesicles they produce are largely anti-inflammatory. NDMVs have been shown to protect cartilage during inflammatory arthritis. They exert these effects by inhibiting or affecting the function of target cells, including macrophages. NDMVs have the potential to act as disease-modifying agents, especially for inflammatory diseases. This protocol describes a method using differential centrifugation to separate neutrophils from whole human blood. Subsequently, neutrophils are identified by cytospin and Wright's staining, and then the NDMVs are isolated using differential centrifugation., Competing Interests: Competing interestsThe authors declare no conflict of interest., (Copyright © 2021 The Authors; exclusive licensee Bio-protocol LLC.)
- Published
- 2021
- Full Text
- View/download PDF
18. Behçet's syndrome in children and young people in the United Kingdom and the Republic of Ireland: a prospective epidemiological study.
- Author
-
Pain CE, Beresford MW, Fortune F, Lai ETC, Murphy R, Taylor-Robinson D, Brogan PA, and Moots RJ
- Subjects
- Adolescent, Behcet Syndrome diagnosis, Behcet Syndrome pathology, Child, Child, Preschool, Delayed Diagnosis statistics & numerical data, Disease Progression, Epidemiologic Studies, Female, Follow-Up Studies, Humans, Incidence, Ireland epidemiology, Male, Patient Acceptance of Health Care statistics & numerical data, Prevalence, Prospective Studies, United Kingdom epidemiology, Behcet Syndrome epidemiology, Population Surveillance
- Abstract
Objectives: To define the incidence and prevalence of Behçet's syndrome (BS) in children and young people (CYP) up to the age of 16 years in the United Kingdom (UK) and Republic of Ireland (ROI)., Methods: A prospective epidemiological study was undertaken with the support of the British Paediatric Surveillance Unit (BPSU) and the British Society of Paediatric Dermatologists (BSPD). Consultants reported anonymised cases of BS seen. A follow-up study at one year examined progression of disease and treatment., Results: Over a two-year period, 56 cases met the International Criteria for Behçet's Disease. For children under 16 years of age, the two-year period prevalence estimate was 4.2 per million (95% CI: 3.2, 5.4) and the incidence was 0.96 per million person years (95% CI: 0.66, 1.41). Mucocutaneous disease was the most common phenotype (56/100%), with ocular (10/56; 17.9%), neurological (2/56; 3.6%) and vascular involvement (3/56; 5.4%) being less common. Median age at onset was 6.34 years and at diagnosis was 11.72 years. There were slightly more female than male children reported (32/56; 55.6%). The majority of cases (85.7%) were white Caucasian. Apart from genital ulcers, which were more common in females, there were no significant differences in frequency of manifestations between male or females, nor between ethnicities. Over 83% of cases had three or more non-primary care healthcare professionals involved in their care., Conclusion: BS is extremely rare in CYP in the UK and ROI and most have mucocutaneous disease. Healthcare needs are complex, and coordinated care is key., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
19. A Darwinian View of Behçet's Disease.
- Author
-
Smith R, Moots RJ, Murad M, and Wallace GR
- Abstract
Behçet's disease (BD) is a multisystem inflammatory disorder of unknown etiology, characterized by oral and genital ulceration, with other complications including eye, skin, joint, and central nervous system (CNS) lesions. Diagnosis is based on clinical findings, which may differ between patients. There is a strong genetic basis for BD; however, only a few genes have been associated with the disease across the geographical spread of BD. In this article, we discuss the history and combination of genes involved in this complex disease in relation to the geographical range and present our view that the disease has developed from a Darwinian perspective, with different gene polymorphisms that affect the same biological pathway. Moreover, these mutations individually are protective mechanisms against the disease relevant to each region, which affected both archaic and modern humans., Competing Interests: Conflict of Interest Robert J. Moots is the Co-Editor-in-Chief of the journal. The article was subject to the journal's standard procedures, with peer review handled independently of this editor and his research groups., (© 2021 Rhodri Smith et al., published by Sciendo.)
- Published
- 2021
- Full Text
- View/download PDF
20. Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS.
- Author
-
Zhao SS, Jones GT, Macfarlane GJ, Hughes DM, Moots RJ, and Goodson NJ
- Subjects
- Adult, Comorbidity, Female, Humans, Male, Middle Aged, Quality of Life, Registries, Severity of Illness Index, Spondylarthritis diagnosis, Spondylarthritis drug therapy, Treatment Outcome, Antirheumatic Agents therapeutic use, Spondylarthritis epidemiology, Tumor Necrosis Factor Inhibitors therapeutic use
- Abstract
Objective: Comorbidities influence disease assessment in axial spondyloarthritis (axSpA), but their association with response to TNF inhibitors (TNFi) is unclear. We examined associations between comorbidity history at TNFi initiation and: (i) change in disease indices over time; (ii) binary response definitions; and (iii) time to treatment discontinuation., Methods: We studied participants starting their first TNFi from a national axSpA register. Comorbidity categories were created from 14 physician-diagnosed conditions and compared against: change in disease indices over time using linear mixed effects models; BASDAI50/2 (50% or 2-unit reduction) and BASDAI < 4 at 6 months using logistic models; and time to treatment discontinuation using Cox models. Models were adjusted for age, gender, BMI, deprivation and education., Results: In total, 994 were eligible for analysis (68% male, mean age 45 years); 21% had one comorbidity and 11% had ≥2. Baseline disease severity was higher in those with comorbidities across all indices, but absolute improvement over time was comparable for BASDAI and spinal pain. Participants with ≥2 comorbidities had smaller absolute improvement in BASFI and quality of life. This group also had numerically reduced odds of achieving BASDAI50/2 [odds ratio (OR) 0.81; 95% CI: 0.45, 1.45] and BASDAI < 4 (OR 0.57; 95% CI: 0.32, 1.04). Treatment discontinuation was increased in those with two comorbidities [hazard ratio (HR) 1.32; 95% CI: 0.88, 2.00] and ≥3 comorbidities (HR 2.18; 95% CI: 1.20, 3.93) compared with none., Conclusions: Participants with multiple comorbidities had poorer treatment outcomes, particularly increased treatment discontinuation and poorer improvements in function and quality of life. These results inform clinicians and educate patients about response to the first TNFi given comorbidity burden., (© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2021
- Full Text
- View/download PDF
21. Internalization of Neutrophil-Derived Microvesicles Modulates TNFα-Stimulated Proinflammatory Cytokine Production in Human Fibroblast-Like Synoviocytes.
- Author
-
Zhan D, Cross A, Wright HL, Moots RJ, Edwards SW, and Honsawek S
- Subjects
- Cell-Derived Microparticles pathology, Cells, Cultured, Fibroblasts drug effects, Fibroblasts immunology, Fibroblasts pathology, Humans, Neutrophils pathology, Osteoarthritis, Knee drug therapy, Osteoarthritis, Knee immunology, Osteoarthritis, Knee pathology, Synoviocytes drug effects, Synoviocytes immunology, Synoviocytes pathology, Cell-Derived Microparticles metabolism, Fibroblasts metabolism, Inflammation Mediators metabolism, Neutrophils metabolism, Osteoarthritis, Knee metabolism, Synoviocytes metabolism, Tumor Necrosis Factor-alpha pharmacology
- Abstract
Neutrophil-derived microvesicles (NDMVs) have the potential to exert anti-inflammatory effects. Our study aimed to explore the effects of NDMVs on proinflammatory cytokines expressed by tumor necrosis factor α (TNFα)-stimulated fibroblast-like synoviocytes (FLS). FLS were isolated from the synovium of knee osteoarthritis (OA) patients undergoing surgery. NDMVs, isolated from TNFα-stimulated healthy neutrophils, were characterized by electron microscopy and nanoparticle tracking analysis. MTT and scratch wound healing assays were used to measure FLS viability and migration after treatment with NDMVs, while internalization of fluorescently labeled NDMVs was appraised by flow cytometry and confocal microscopy. Levels of proinflammatory cytokines in supernatants were quantified by the Bio-Plex system. Incubation of FLS with NDMVs at a vesicle/cell ratio of 100 resulted in a time-dependent uptake, with 35% of synoviocytes containing microvesicles over a 6-24 h time period, with no significant change in cell viability. TNFα stimulated the cytokine expression in FLS, and NDMVs down-regulated TNFα-induced expression of IL-5, IL-6, IL-8, MCP-1, IFNγ and MIP-1β. However, this down-regulation was selective, as NDMVs had no significant effects on TNFα-stimulated expression of IL-2 or IL-4. NDMVs were internalized by FLS to inhibit TNFα-stimulated broad-spectrum proinflammatory cytokine secretion. NDMVs, therefore, may exhibit an anti-inflammatory role in the regulation of the FLS function.
- Published
- 2021
- Full Text
- View/download PDF
22. Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS.
- Author
-
Zhao SS, Jones GT, Macfarlane GJ, Hughes DM, Moots RJ, and Goodson NJ
- Subjects
- Adult, Aged, Blood Sedimentation, C-Reactive Protein immunology, Comorbidity, Female, Humans, Linear Models, Male, Middle Aged, Severity of Illness Index, Spondylarthropathies epidemiology, Spondylarthropathies immunology, Depressive Disorder epidemiology, Heart Failure epidemiology, Peptic Ulcer epidemiology, Spondylarthropathies physiopathology
- Abstract
Objective: Whether comorbidities influence disease activity assessment in axial SpA (axSpA) is unclear. Comorbidities inflate DAS28 in rheumatoid arthritis through the patient global score. We examined whether axSpA disease activity measures are differentially affected, and whether comorbidities inflate the AS disease activity score (ASDAS) through the patient global component., Methods: We used baseline data from the British Society for Rheumatology Biologics Register for AS, including 14 physician diagnosed comorbidities. Linear models were used to compare disease activity (BASDAI, spinal pain, ASDAS) and ESR/CRP according to comorbidity count, adjusted for age, gender, BMI, smoking, socioeconomic status, and education. The same models were used to examine whether the patient global score was associated with comorbidities, additionally adjusting for other ASDAS components., Results: The number of participants eligible for analysis was 2043 (67% male, mean age 49 years); 44% had at least one comorbidity. Each additional comorbidity was associated with higher BASDAI by 0.40 units (95% CI: 0.27, 0.52) and spinal pain by 0.53 (95% CI: 0.37, 0.68). Effect size for ASDAS (0.09 units; 95% CI: 0.03, 0.15) was not clinically significant. ESR and CRP were not associated with comorbidity count. Depression, heart failure and peptic ulcer were consistently associated with higher disease activity measures, but not CRP/ESR. Patient global was associated with comorbidity count, but not independently of other ASDAS components (P = 0.75)., Conclusion: Comorbidities were associated with higher patient reported disease activity in axSpA. Clinicians should be mindful of the potential impact of comorbidities on patient reported outcome measures and consider additionally collecting ASDAS when comorbidities are present., (© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2021
- Full Text
- View/download PDF
23. Type I interferon regulates cytokine-delayed neutrophil apoptosis, reactive oxygen species production and chemokine expression.
- Author
-
Glennon-Alty L, Moots RJ, Edwards SW, and Wright HL
- Subjects
- Apoptosis, Cells, Cultured, Chemokines genetics, Chemokines metabolism, Gene Expression Regulation, Granulocyte-Macrophage Colony-Stimulating Factor genetics, Healthy Volunteers, Humans, MAP Kinase Signaling System, Myeloid Cell Leukemia Sequence 1 Protein metabolism, Tumor Necrosis Factor-alpha genetics, Arthritis, Rheumatoid immunology, Granulocyte-Macrophage Colony-Stimulating Factor metabolism, Interferon-alpha metabolism, Lupus Erythematosus, Systemic immunology, Neutrophils immunology, Reactive Oxygen Species metabolism, Tumor Necrosis Factor-alpha metabolism
- Abstract
Interferons (IFNs) are key regulators of a number of inflammatory conditions in which neutrophils play an important role in pathology, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), where type I IFNs are implicated in disease pathology. However, IFNs are usually generated in vivo together with other cytokines that also have immunoregulatory functions, but such interactions are poorly defined experimentally. We measured the effects of type I (IFN-α) IFN, elevated in both RA and SLE, on the functions of healthy neutrophils incubated in vitro in the absence and presence of proinflammatory cytokines typically elevated in inflammatory diseases [tumour necrosis factor (TNF-α), granulocyte-macrophage colony-stimulating factor (GM-CSF)]. IFN-α alone had no effect on neutrophil apoptosis; however, it abrogated the anti-apoptotic effect of GM-CSF (18 h, P < 0·01). The enhanced stability of the anti-apoptotic protein myeloid cell leukaemia 1 (Mcl-1) and delayed activation of caspase activation normally regulated by GM-CSF were blocked by IFN-α: this effect was mediated, in part, by activation of p38 mitogen-activated protein kinase (MAPK). IFN-α alone also primed reactive oxygen species (ROS) production and maintained the transient priming effect of TNF-α for up to 4 h: it also down-regulated GM-CSF- and TNF-α-activated expression of chemokine (C-X-C motif) ligand (CXCL)1, CXCL2, CXCL3, CXCL8, CCL3 and CCL4 but, in contrast, increased the expression of CXCL10. These novel data identify complex regulatory signalling networks in which type I IFNs profoundly alter the response of neutrophils to inflammatory cytokines. This is likely to have important consequences in vivo and may explain the complexity and heterogeneity of inflammatory diseases such as RA, in which multiple cytokine cascades have been activated., (© 2020 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology.)
- Published
- 2021
- Full Text
- View/download PDF
24. Rheumatoid Arthritis Synovial Fluid Neutrophils Drive Inflammation Through Production of Chemokines, Reactive Oxygen Species, and Neutrophil Extracellular Traps.
- Author
-
Wright HL, Lyon M, Chapman EA, Moots RJ, and Edwards SW
- Subjects
- Apoptosis immunology, Female, Humans, Joints immunology, Male, Middle Aged, Neutrophil Activation immunology, Peroxidase immunology, Signal Transduction immunology, Synovial Membrane immunology, Arthritis, Rheumatoid immunology, Chemokines immunology, Extracellular Traps immunology, Inflammation immunology, Neutrophils immunology, Reactive Oxygen Species immunology, Synovial Fluid immunology
- Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disorder affecting synovial joints. Neutrophils are believed to play an important role in both the initiation and progression of RA, and large numbers of activated neutrophils are found within both synovial fluid (SF) and synovial tissue from RA joints. In this study we analyzed paired blood and SF neutrophils from patients with severe, active RA (DAS28>5.1, n=3) using RNA-seq. 772 genes were significantly different between blood and SF neutrophils. IPA analysis predicted that SF neutrophils had increased expression of chemokines and ROS production, delayed apoptosis, and activation of signaling cascades regulating the production of NETs. This activated phenotype was confirmed experimentally by incubating healthy control neutrophils in cell-free RA SF, which was able to delay apoptosis and induce ROS production in both unprimed and TNFα primed neutrophils (p<0.05). RA SF significantly increased neutrophil migration through 3μM transwell chambers (p<0.05) and also increased production of NETs by healthy control neutrophils (p<0.001), including exposure of myeloperoxidase (MPO) and citrullinated histone-H3-positive DNA NETs. IPA analysis predicted NET production was mediated by signaling networks including AKT, RAF1, SRC, and NF-κB. Our results expand the understanding of the molecular changes that take place in the neutrophil transcriptome during migration into inflamed joints in RA, and the altered phenotype in RA SF neutrophils. Specifically, RA SF neutrophils lose their migratory properties, residing within the joint to generate signals that promote joint damage, as well as inflammation via recruitment and activation of both innate and adaptive immune cells. We propose that this activated SF neutrophil phenotype contributes to the chronic inflammation and progressive damage to cartilage and bone observed in patients with RA., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Wright, Lyon, Chapman, Moots and Edwards.)
- Published
- 2021
- Full Text
- View/download PDF
25. Biomarkers for Treatment Response in Rheumatoid Arthritis: Where are they?
- Author
-
Zhao SS and Moots RJ
- Abstract
Competing Interests: Conflict of Interest None declared.
- Published
- 2020
- Full Text
- View/download PDF
26. An update on the general management approach to common vasculitides.
- Author
-
Hng M, Zhao SS, and Moots RJ
- Subjects
- Adult, Humans, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis diagnosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis drug therapy, Giant Cell Arteritis diagnosis, Giant Cell Arteritis therapy
- Abstract
Primary systemic vasculitides (PSV) are multisystem diseases associated with high morbidity and mortality, particularly if not treated in a timely manner. In recent decades, clinical trials have delivered considerable evidence to underpin optimal diagnostic and therapeutic approaches. This article provides a brief overview of PSV in adults, focusing on the latest updates and recommendations for the management of antineutrophil cytoplasmic antibody-associated vasculitis and giant cell arteritis., (© Royal College of Physicians 2020. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
27. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis.
- Author
-
Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, and Goodson NJ
- Subjects
- Comorbidity, Humans, Hyperlipidemias epidemiology, Hypertension epidemiology, Obesity epidemiology, Prevalence, Spondylarthritis epidemiology
- Abstract
Objectives: Comorbidities are common in people with axial spondyloarthritis (axSpA). In this systematic review and meta-analysis, we aimed to: (i) describe the prevalence of commonly reported comorbidities, (ii) compare comorbidities between axSpA and control populations, and (iii) examine the impact of comorbidity burden on axSpA outcomes., Methods: We systematically searched Medline, PubMed, Scopus and Web of Science using a predefined protocol in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. We excluded studies of only one comorbid condition or a few closely related diseases within one organ system. Where possible, meta-analysis was performed using random-effects models., Results: A total of 40 studies were included for analysis. 36 studies reported prevalence of comorbidities, amounting to a combined sample size of 119 427 patients. The number of comorbidities studied ranged from 3 to 43. The most prevalent individual comorbidities were hypertension (pooled prevalence 23%), hyperlipidaemia (17%) and obesity (14%). Eleven studies consistently showed higher prevalence of comorbidities in axSpA than controls, particularly large differences were seen for depression [pooled odds ratio (OR) 1.80] and heart failure (OR 1.84). Comorbidities (total number of and individual conditions) were also associated with axSpA disease activity, functional impairment, quality of life, work productivity and mortality., Conclusions: Comorbidities are common in axSpA, particularly cardiovascular diseases and risk factors. Most comorbidities were more prevalent in axSpA patients than in control populations. Overall comorbidity burden, and many individual conditions, were associated with axSpA outcomes including worse disease severity, work productivity and mortality., (© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2020
- Full Text
- View/download PDF
28. Impact of Smoking in Response to Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Methodologic Considerations for Longitudinal Observational Studies.
- Author
-
Zhao SS, Yoshida K, Jones GT, Hughes DM, Tedeschi SK, Lyu H, Moots RJ, Solomon DH, and Goodson NJ
- Subjects
- Adult, Female, Humans, Longitudinal Studies, Male, Middle Aged, Registries, Severity of Illness Index, Spondylarthritis diagnosis, Treatment Outcome, United Kingdom, Antirheumatic Agents therapeutic use, Smoking, Spondylarthritis drug therapy, Tumor Necrosis Factor Inhibitors therapeutic use
- Abstract
Objective: Observational data facilitate examination of treatment-effect heterogeneity, but the risk of bias is substantial. The present study was undertaken to highlight methodologic considerations through an analysis of whether smoking affects response to tumor necrosis factor inhibitors (TNFi) in axial spondyloarthritis (SpA)., Methods: We used longitudinal data from the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis. Participants fulfilling the Assessment of SpondyloArthritis international Society criteria for axial SpA who started their first TNFi were eligible for analysis. In comparing the impact of smoking status, weighted generalized estimating equations were used to examine changes in several continuous outcome measures, including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS). Inverse probability weights were used to account for differences in baseline covariates and excluded participants. We separately assessed response in the first 3 months to account for nonrandom dropout., Results: For 840 participants who started on TNFi, 1,641 assessments from 627 individuals were analyzed (69% male, mean age 46 years). A total of 33% were current smokers and 30% ex-smokers. Ex-smokers and current smokers had worse disease than never smokers at baseline. Accounting for these differences, response did not differ according to smoking status. Compared to never smokers, ex-smokers (β = -0.6, 95% confidence interval [95% CI] -1.4, 0.3) and current smokers (β = -0.4, 95% CI -1.1, 0.4) had a similar response according to the BASDAI and ASDAS (ex-smokers β = -0.1, 95% CI -0.5, 0.3; current smokers β = -0.01, 95% CI -0.4, 0.4) at 3 months., Conclusion: TNFi response did not differ according to baseline smoking status in this UK cohort. Conflicting results from previous studies were likely due to methodologic differences. This analysis highlights potential sources of bias that should be addressed in future studies., (© 2019, American College of Rheumatology.)
- Published
- 2020
- Full Text
- View/download PDF
29. A novel treatment in the management of genital ulceration in Behçet's disease.
- Author
-
Benson RM, Kirwan J, and Moots RJ
- Subjects
- Female, Genital Diseases, Female, Genital Diseases, Male, Genitalia, Humans, Male, Behcet Syndrome, Ulcer drug therapy
- Published
- 2019
30. Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States.
- Author
-
Zhao SS, Ermann J, Xu C, Lyu H, Tedeschi SK, Liao KP, Yoshida K, Moots RJ, Goodson NJ, and Solomon DH
- Subjects
- Adult, Aged, Chronic Disease drug therapy, Comorbidity, Cross-Sectional Studies, Female, Humans, Inflammation Mediators blood, Male, Middle Aged, Spondylarthritis blood, Spondylarthritis drug therapy, Spondylitis, Ankylosing blood, Spondylitis, Ankylosing drug therapy, United States, Antirheumatic Agents therapeutic use, Biological Products therapeutic use, Chronic Disease epidemiology, Spondylarthritis epidemiology, Spondylitis, Ankylosing epidemiology
- Abstract
Objectives: This study aimed to compare comorbidities and biologic DMARD (bDMARD) use between AS and non-radiographic axial SpA (nr-axSpA) patients, using a large cohort of patients from routine clinical practice in the United States., Methods: We performed a cross-sectional study using electronic medical records from two academic hospitals in the United States. Data were extracted using automated searches (⩾3 ICD codes combined with text searches) and supplemented with manual chart review. Patients were categorized into AS or nr-axSpA according to classification criteria. Disease features, comorbidities (from a list of 39 chronic conditions) and history of bDMARD prescription were compared using descriptive statistics., Results: Among 965 patients identified, 775 (80%) were classified as having axSpA. The cohort was predominantly male (74%) with a mean age of 52.5 years (s.d. 16.8). AS patients were significantly older (54 vs 46 years), more frequently male (77% vs 64%) and had higher serum inflammatory markers than those with nr-axSpA (median CRP 3.4 vs 2.2 mg/dl). Half of all patients had at least one comorbidity. The mean number of comorbidities was 1.5 (s.d. 2.2) and similar between AS and nr-axSpA groups. A history of bDMARD-use was seen in 55% of patients with no difference between groups. The most commonly prescribed bDMARDs were adalimumab (31%) and etanercept (29%). Ever-prescriptions of individual bDMARDs were similar between AS and nr-axSpA., Conclusion: Despite age differences, nr-axSpA patients had similar comorbidity burdens as those with AS. Both groups received comparable bDMARD treatment in this United States clinic-based cohort., (© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
31. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
- Author
-
Strand V, Mysler E, Moots RJ, Wallenstein GV, DeMasi R, Gruben D, Soma K, Iikuni N, Smolen JS, and Fleischmann R
- Subjects
- Adalimumab administration & dosage, Arthritis, Rheumatoid diagnosis, Drug Therapy, Combination, Humans, Methotrexate administration & dosage, Middle Aged, Piperidines administration & dosage, Pyrimidines administration & dosage, Pyrroles administration & dosage, Severity of Illness Index, Treatment Outcome, Adalimumab therapeutic use, Arthritis, Rheumatoid drug therapy, Methotrexate therapeutic use, Piperidines therapeutic use, Pyrimidines therapeutic use, Pyrroles therapeutic use
- Abstract
Objective: To provide the first direct comparison of patient-reported outcomes (PROs) following treatment with tofacitinib monotherapy versus tofacitinib or adalimumab (ADA) in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) with inadequate response to MTX (MTX-IR)., Methods: ORAL Strategy (NCT02187055), a phase IIIB/IV, head-to-head, randomised controlled trial, assessed non-inferiority between tofacitinib 5 mg two times per day monotherapy, tofacitinib 5 mg two times per day+MTX and ADA 40 mg every other week+MTX. PROs assessed included the following: Patient Global Assessment of disease activity (PtGA), Pain, Health Assessment Questionnaire-Disability Index, Functional Assessment of Chronic Illness Therapy-Fatigue and 36-Item Short-Form Health Survey (SF-36) summary and domain scores., Results: Substantial improvements from baseline were reported across all PROs in all treatment arms, which, in the majority, met or exceeded minimum clinically important differences. Compared with tofacitinib monotherapy, tofacitinib+MTX combination treatment conferred significantly greater improvements in PtGA, Pain and SF-36 physical component summary scores at month 6. Statistically or numerically greater improvements were often, but not uniformly, reported for combination treatments compared with tofacitinib monotherapy at other time points., Conclusion: Treatment with tofacitinib+MTX, ADA+MTX and tofacitinib monotherapy resulted in clinically meaningful improvements in PROs in MTX-IR patients with RA. These were comparatively greater with combination treatments versus tofacitinib monotherapy, although differences between treatment arms were small, limiting our ability to confer clinical meaning., Trial Registration Number: NCT02187055., Competing Interests: Competing interests: VS has received consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Corrona, Eli Lilly, Genentech/Roche, GSK, Janssen, Merck, Novartis, Pfizer Inc, Regeneron, Samsung, Sandoz, Sanofi and UCB. EM has received research grants, consulting fees or other remuneration from, and is a member of the speakers’ bureau for, AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, MedImmune, Pfizer Inc and Roche. RJM has received research grants and consulting fees from, or is a member of the speakers’ bureau for, AbbVie, AKL Pharma, Biogen, Bristol-Myers Squibb, Chugai, Eli Lilly, Novartis, Pfizer Inc, Roche, Sandoz, Sanofi and UCB. DG, KS and NI are employees and shareholders of Pfizer Inc. GVW and RD were employees and shareholders of Pfizer Inc at the time of the analysis. JSS has received consulting fees, speaking fees and honoraria from AbbVie, Amgen, AstraZeneca, Astro, Celgene, Celltrion, Eli Lilly, GSK, ILTOO, Janssen, MedImmune, MSD, Novartis-Sandoz, Pfizer Inc, Roche, Samsung, Sanofi and UCB Pharma; and has received institutional grants from AbbVie, Eli Lilly, Janssen, MSD, Pfizer Inc and Roche. RF has received research grants or consulting fees from AbbVie, ACEA, Amgen, AstraZeneca, Bristol-Myers Squibb, Celltrion, Eli Lilly, Genentech, GSK, Janssen, Novartis, Pfizer Inc, Samsung, Sanofi-Aventis, Tahio and UCB., (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
32. Comorbidity burden in axial spondyloarthritis: a cluster analysis.
- Author
-
Zhao SS, Radner H, Siebert S, Duffield SJ, Thong D, Hughes DM, Moots RJ, Solomon DH, and Goodson NJ
- Subjects
- Adult, Anxiety epidemiology, Cluster Analysis, Comorbidity, Coronary Disease epidemiology, Cross-Sectional Studies, Female, Fibromyalgia epidemiology, Humans, Irritable Bowel Syndrome epidemiology, Linear Models, Male, Middle Aged, Patient Reported Outcome Measures, Quality of Life, Spondylarthritis psychology, United Kingdom epidemiology, Cost of Illness, Depression epidemiology, Hypertension epidemiology, Severity of Illness Index, Spondylarthritis epidemiology
- Abstract
Objectives: To examine how comorbidities cluster in axial spondyloarthritis (axSpA) and whether these clusters are associated with quality of life, global health and other outcome measures., Methods: We conducted a cross-sectional study of consecutive patients meeting ASAS criteria for axSpA in Liverpool, UK. Outcome measures included quality of life (EQ5D), global health and disease activity (BASDAI). We used hierarchical cluster analysis to group patients according to 38 pre-specified comorbidities. In multivariable linear models, the associations between distinct comorbidity clusters and each outcome measure were compared, using axSpA patients with no comorbidities as the reference group. Analyses were adjusted for age, gender, symptom duration, BMI, deprivation, NSAID-use and smoking., Results: We studied 419 patients (69% male, mean age 46 years). 255 patients (61%) had at least one comorbidity, among whom the median number was 1 (range 1-6). Common comorbidities were hypertension (19%) and depression (16%). Of 15 clusters identified, the most prevalent clusters were hypertension-coronary heart disease and depression-anxiety. Compared with patients with no comorbidities, the fibromyalgia-irritable bowel syndrome cluster was associated with adverse patient-reported outcome measures; these patients reported 1.5-unit poorer global health (95%CI 0.01, 2.9), reduced quality of life (0.25-unit lower EQ5D; 95%CI -0.37, -0.12) and 1.8-unit higher BASDAI (95% CI 0.4, 3.3). Similar effect estimates were found for patients in the depression-anxiety cluster., Conclusion: Comorbidity is common among axSpA patients. The two most common comorbidities were hypertension and depression. Patients in the depression-anxiety and fibromyalgia-IBS clusters reported poorer health and increased axSpA severity., (© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
33. Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis.
- Author
-
Zhao SS, Yoshida K, Jones GT, Hughes DM, Duffield SJ, Tedeschi SK, Lyu H, Moots RJ, Solomon DH, and Goodson NJ
- Subjects
- Adult, Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Smoking adverse effects, Spondylarthritis drug therapy, Tumor Necrosis Factor Inhibitors therapeutic use, Withholding Treatment
- Abstract
Background: The impact of smoking on TNF inhibition (TNFi) therapy is unclear. We examined the effect of smoking on all-cause and cause-specific TNFi discontinuation in axial spondyloarthritis (axSpA)., Methods: We used longitudinal data from the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS). Patients fulfilling the ASAS criteria for axSpA, who started their first TNFi, were eligible for analysis. Inverse-probability weights were used to balance differences in baseline disease severity and other confounders. We used marginal structural Cox proportional hazard models to estimate hazard ratios (HR) for TNFi discontinuation according to smoking status. In analyses of cause-specific discontinuation, competing risk events were considered as censoring, using inverse-probability weights., Results: A total of 758 participants were included in the analysis (66% male, mean age 45 years), providing 954 patient-years of follow-up. TNFi was discontinued in 174 (23%) patients, among whom 26% stopped due to infections, 20% due to other adverse events and 44% due to inefficacy or other reasons. Thirty-four percent were current smokers and 30% ex-smokers. Compared to never smokers, current smokers' risk of TNFi discontinuation was HR 0.79 (95%CI 0.53 to 1.20) and ex-smokers HR 0.68 (95%CI 0.45 to 1.04). Our data did not show evidence that current smoking influenced discontinuation due to infections (HR 0.79, 95%CI 0.40 to 1.54), other adverse events (HR 0.86, 95%CI 0.41 to 1.78) or inefficacy/other causes (HR 1.44, 95%CI 0.86 to 2.41)., Conclusion: Baseline smoking status did not impact TNFi discontinuation in this UK cohort of axSpA participants.
- Published
- 2019
- Full Text
- View/download PDF
34. Human neutrophils activated via TLR8 promote Th17 polarization through IL-23.
- Author
-
Tamassia N, Arruda-Silva F, Wright HL, Moots RJ, Gardiman E, Bianchetto-Aguilera F, Gasperini S, Capone M, Maggi L, Annunziato F, Edwards SW, and Cassatella MA
- Subjects
- Humans, Monocytes cytology, Monocytes immunology, Neutrophils cytology, Th17 Cells immunology, Toll-Like Receptor 8 agonists, Tumor Necrosis Factor-alpha immunology, Interleukin-12 Subunit p40 immunology, Interleukin-23 Subunit p19 immunology, Neutrophil Activation, Neutrophils immunology, Toll-Like Receptor 8 immunology
- Abstract
Human neutrophils contribute to the regulation of inflammation via the generation of a range of cytokines that affect all elements of the immune system. Here, we investigated their ability to express some of the members of the IL-12 family after incubation with TLR8 agonists. Highly pure human neutrophils were thus incubated for up to 48 h with or without R848, or other TLR8 agonists, to then measure the expression levels of transcripts and proteins for IL-12 family member subunits by RNA-seq, reverse transcription quantitative PCR, and ELISA. We show a TLR8-mediated inducible expression of IL-12B and IL-23A, but not IL-12A, mRNA, which occurs via chromatin remodeling (as assessed by ChIP-seq), and subsequent production of IL-23 and IL-12B, but no IL-12, proteins. Induction of IL-23 requires endogenous TNF-α, as both mRNA and protein levels were blocked in TLR8-activated neutrophils via a TNF-α-neutralizing Ab. We also show that supernatants from TLR8-activated neutrophils, but not autologous monocytes, induce the differentiation of Th17 cells from naïve T cells in an IL-23-dependent fashion. This study unequivocally demonstrates that highly pure human neutrophils express and produce IL-23, further supporting the key roles played by these cells in the important IL-17/IL-23 network and Th17 responses., (©2019 Society for Leukocyte Biology.)
- Published
- 2019
- Full Text
- View/download PDF
35. Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS).
- Author
-
Zhao S, Jones GT, Macfarlane GJ, Hughes DM, Dean LE, Moots RJ, and Goodson NJ
- Subjects
- Adult, Anxiety etiology, Cohort Studies, Cross-Sectional Studies, Depression etiology, Fatigue etiology, Female, Humans, Male, Middle Aged, Psoriasis etiology, Registries, Uveitis etiology, Severity of Illness Index, Smoking adverse effects, Spondylarthritis etiology, Spondylarthritis pathology
- Abstract
Objective: The effects of smoking on disease manifestations in axial SpA are inadequately described. Utilizing a large and well-characterized cohort, we investigated the association between smoking and extra-axial manifestations, and smoking and disease severity measures., Methods: Baseline data from the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis were explored. Our analyses focused on extra-axial manifestations and other disease severity measures, including scales for fatigue, sleep, anxiety and depression. Logistic and linear models were used to quantify associations between disease characteristics according to smoking status (current/ex/never) and quantity (heavy/light), adjusting for age, gender, BMI, education, deprivation, comorbidities, symptom duration and alcohol status., Results: A total of 2031 participants were eligible for the current analysis (68% male, mean age 49 years). Of these, 24% were current and 32% ex-smokers. When compared with non-smokers, current smokers had lower odds of uveitis [OR 0.7, 95% CI 0.5-0.9] and higher odds of psoriasis (ORadj 1.6, 95% CI 1.1-2.3). Ex- and current smokers had incrementally more severe disease than never smokers, with higher BASDAI (β = 0.3, 95% CI 0.1-0.6; β = 0.9, 95% CI 0.6-1.2) and BASFI (β = 0.5, 95% CI 0.2-0.8; β = 1.3, 95% CI 1.0-1.6); similar associations were observed for fatigue, sleep, anxiety and depression., Conclusion: In this large cross-sectional study, we observed that smoking is independently associated with an adverse disease profile in axial SpA, including worse fatigue, sleep, anxiety and depression, and higher odds of psoriasis. The paradoxical association between current smoking and reduced odds of uveitis is interesting and warrants further investigation., (© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
36. Caught in a Trap? Proteomic Analysis of Neutrophil Extracellular Traps in Rheumatoid Arthritis and Systemic Lupus Erythematosus.
- Author
-
Chapman EA, Lyon M, Simpson D, Mason D, Beynon RJ, Moots RJ, and Wright HL
- Subjects
- Adult, Aged, Apoptosis, Arthritis, Rheumatoid metabolism, DNA metabolism, Extracellular Traps metabolism, Female, Humans, Lupus Erythematosus, Systemic metabolism, Male, Middle Aged, Neutrophils metabolism, Proteomics, Reactive Oxygen Species metabolism, Young Adult, Arthritis, Rheumatoid immunology, Extracellular Traps immunology, Lupus Erythematosus, Systemic immunology, Neutrophils immunology
- Abstract
Neutrophil Extracellular Traps (NETs) are implicated in the development of auto-immunity in diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) through the externalization of intracellular neoepitopes e.g., dsDNA and nuclear proteins in SLE and citrullinated peptides in RA. The aim of this work was to use quantitative proteomics to identify and measure NET proteins produced by neutrophils from healthy controls, and from patients with RA and SLE to determine if NETs can be differentially-generated to expose different sets of neoepitopes. Ultra-pure neutrophils (>99%) from healthy individuals ( n = 3) and patients with RA or SLE ( n = 6 each) were incubated ± PMA (50 nM, PKC super-activator) or A23187 (3.8 μM, calcium ionophore) for 4 h. NETs were liberated by nuclease digestion and concentrated onto Strataclean beads prior to on-bead digestion with trypsin. Data-dependent LC-MS/MS analyses were conducted on a QExactive HF quadrupole-Orbitrap mass spectrometer, and label-free protein quantification was carried out using Progenesis QI. PMA-induced NETs were decorated with annexins, azurocidin and histone H3, whereas A23187-induced NETs were decorated with granule proteins including CAMP/LL37, CRISP3, lipocalin and MMP8, histones H1.0, H1.4, and H1.5, interleukin-8, protein-arginine deiminase-4 (PADI4), and α-enolase. Four proteins were significantly different between PMA-NETs from RA and SLE neutrophils ( p < 0.05): RNASE2 was higher in RA, whereas MPO, leukocyte elastase inhibitor and thymidine phosphorylase were higher in SLE. For A23187-NETs, six NET proteins were higher in RA ( p < 0.05), including CAMP/LL37, CRISP3, interleukin-8, MMP8; Thirteen proteins were higher in SLE, including histones H1.0, H2B, and H4. This work provides the first, direct comparison of NOX2-dependent (PMA) and NOX2-independent (A23187) NETs using quantitative proteomics, and the first direct comparison of RA and SLE NETs using quantitative proteomics. We show that it is the nature of the stimulant rather than neutrophil physiology that determines NET protein profiles in disease, since stimulation of NETosis in either a NOX2-dependent or a NOX2-independent manner generates broadly similar NET proteins irrespective of the disease background. We also use our proteomics pipeline to identify an extensive range of post-translationally modified proteins in RA and SLE, including histones and granule proteins, many of which are known targets of auto-antibodies in each disease.
- Published
- 2019
- Full Text
- View/download PDF
37. Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations.
- Author
-
Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Çelik AF, Fortune F, Gaudric J, Gul A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, and Hatemi G
- Subjects
- Anticoagulants therapeutic use, Behcet Syndrome complications, Clinical Trials as Topic, Eye Diseases etiology, Gastrointestinal Diseases etiology, Glucocorticoids therapeutic use, Humans, Nervous System Diseases etiology, Practice Guidelines as Topic, Vascular Diseases etiology, Behcet Syndrome drug therapy, Eye Diseases drug therapy, Gastrointestinal Diseases drug therapy, Immunosuppressive Agents therapeutic use, Nervous System Diseases drug therapy, Vascular Diseases drug therapy
- Abstract
Objective: To assess the efficacy and safety of treatment modalities for major organ involvement of Behçet's syndrome (BS), in order to inform the update of the EULAR recommendations for the management of BS., Methods: A systematic literature review of all randomized controlled trials, controlled clinical trials, or open label trials assessing eye, vascular, nervous system or gastrointestinal system involvement of BS was performed. If controlled trials were not available for answering a specific research question, uncontrolled studies or case series were also included., Results: We reviewed the titles and abstracts of 3927 references and 161 studies met our inclusion criteria. There were only nine randomized controlled trials. Observational studies with IFN-α and monoclonal anti-TNF antibodies showed beneficial results for refractory uveitis. Meta-analysis of case-control studies showed that immunosuppressives decreased the recurrence rate of deep vein thrombosis significantly whereas anticoagulants did not. CYC and high dose glucocorticoids decreased mortality in pulmonary arterial aneurysms and postoperative complications in peripheral artery aneurysms. Beneficial results for gastrointestinal involvement were obtained with 5-ASA derivatives and AZA as first line treatment and with thalidomide and/or monoclonal anti-TNF antibodies in refractory cases. Observational studies for nervous system involvement showed improved outcome with immunosuppressives and glucocorticoids. Meta-analysis of case-control studies showed an increased risk of developing nervous system involvement with ciclosporin-A., Conclusion: The majority of studies related to major organ involvement that informed the updated EULAR recommendations for the management of BS were observational studies.
- Published
- 2018
- Full Text
- View/download PDF
38. The Behçet's centres of excellence.
- Author
-
Moots RJ, Fortune F, and Situnayake D
- Subjects
- Humans, United Kingdom, Behcet Syndrome therapy, Delivery of Health Care standards, Quality of Health Care, Referral and Consultation standards, Rheumatology, Societies, Medical
- Published
- 2018
- Full Text
- View/download PDF
39. Etanercept for the treatment of rheumatoid arthritis.
- Author
-
Zhao S, Mysler E, and Moots RJ
- Subjects
- Animals, Etanercept pharmacology, Humans, Quality of Life, Treatment Outcome, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Biosimilar Pharmaceuticals therapeutic use, Etanercept therapeutic use
- Abstract
Etanercept was the first specific anticytokine therapy approved for the treatment of rheumatoid arthritis (RA). Its clinical efficacy and safety has been demonstrated by several clinical trials in early as well as established disease. Etanercept, along with other TNF inhibitors, have revolutionized management of RA and dramatically improved disease activity, function, quality of life and mortality for these patients. It is structurally distinct from other TNF inhibitors and thus has desirable profiles for immunogenicity, drug survival and infection rate. With the increasing number of etanercept biosimilars, there will likely be a resurgence of their prescription. This article reviews the pharmacology, efficacy and safety of the etanercept reference product, and its biosimilars, in the context of RA treatment.
- Published
- 2018
- Full Text
- View/download PDF
40. Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy.
- Author
-
Bezzina OM, Gallagher P, Mitchell S, Bowman SJ, Griffiths B, Hindmarsh V, Hargreaves B, Price EJ, Pease CT, Emery P, Lanyon P, Bombardieri M, Sutcliffe N, Pitzalis C, Hunter J, Gupta M, McLaren J, Cooper AM, Regan M, Giles IP, Isenberg DA, Saravanan V, Coady D, Dasgupta B, McHugh NJ, Young-Min SA, Moots RJ, Gendi N, Akil M, MacKay K, Ng WF, and Robinson LJ
- Subjects
- Aged, Fatigue diagnosis, Fatigue epidemiology, Female, Humans, Male, Middle Aged, Pain diagnosis, Pain epidemiology, Registries, Sjogren's Syndrome epidemiology, United Kingdom epidemiology, Xerophthalmia epidemiology, Xerostomia epidemiology, Diagnostic Self Evaluation, Sjogren's Syndrome diagnosis, Xerophthalmia diagnosis, Xerostomia diagnosis
- Abstract
Objective: To develop a novel method for capturing the discrepancy between objective tests and subjective dryness symptoms (a sensitivity scale) and to explore predictors of dryness sensitivity., Methods: Archive data from the UK Primary Sjögren's Syndrome Registry (n = 688) were used. Patients were classified on a scale from -5 (stoical) to +5 (sensitive) depending on the degree of discrepancy between their objective and subjective symptoms classes. Sensitivity scores were correlated with demographic variables, disease-related factors, and symptoms of pain, fatigue, anxiety, and depression., Results: Patients were on average relatively stoical for both types of dryness symptoms (mean ± SD ocular dryness -0.42 ± 2.2 and -1.24 ± 1.6 oral dryness). Twenty-seven percent of patients were classified as sensitive to ocular dryness and 9% to oral dryness. Hierarchical regression analyses identified the strongest predictor of ocular dryness sensitivity to be self-reported pain and that of oral dryness sensitivity to be self-reported fatigue., Conclusion: Ocular and oral dryness sensitivity can be classified on a continuous scale. The 2 symptom types are predicted by different variables. A large number of factors remain to be explored that may impact symptom sensitivity in primary Sjögren's syndrome, and the proposed method could be used to identify relatively sensitive and stoical patients for future studies., (© 2016, The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.)
- Published
- 2017
- Full Text
- View/download PDF
41. Building a rheumatology team for East Africa: A call for action!
- Author
-
Genga EK, Moots RJ, Oyoo OG, and Otieno FO
- Subjects
- Africa, Eastern, Humans, Workforce, Rheumatic Diseases therapy, Rheumatology
- Published
- 2017
- Full Text
- View/download PDF
42. Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
- Author
-
Mitchell TS, Moots RJ, and Wright HL
- Subjects
- Adult, Aged, Aged, 80 and over, Azetidines pharmacology, Case-Control Studies, Cell Movement, Cells, Cultured, Female, Granulocyte-Macrophage Colony-Stimulating Factor metabolism, Humans, Interleukin-8 metabolism, Male, Middle Aged, Piperidines pharmacology, Protein Kinase Inhibitors pharmacology, Purines, Pyrazoles, Pyrimidines pharmacology, Pyrroles pharmacology, Sulfonamides pharmacology, Tetradecanoylphorbol Acetate metabolism, United Kingdom, Arthritis, Rheumatoid immunology, Janus Kinases antagonists & inhibitors, Neutrophils drug effects, Reactive Oxygen Species metabolism, Respiratory Burst drug effects
- Abstract
Neutrophils play a crucial role in the pathophysiology of rheumatoid arthritis (RA) via the release of reactive oxygen species (ROS), proteases and cytokines. Orally active Janus kinase (JAK) inhibitors (JAKi), e.g. baricitinib and tofacitinib, have high clinical efficacy in RA but are linked with neutropenia and increased infections. Our aim was to determine the effect of JAK inhibition with baricitinib and tofacitinib on healthy control and RA neutrophil lifespan and function. RA (n = 7) and healthy control (n = 7) neutrophils were treated with baricitinib or tofacitinib for 30 min, prior to incubation in the absence or presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) or interferon (IFN)-γ. JAKi prevented GM-CSF- and IFN-γ-induced apoptosis delay in RA and healthy control neutrophils in a dose-dependent manner. Baricitinib decreased the rate of chemotaxis towards interleukin (IL)-8, but not f-Met-Leu-Phe (fMLP) in RA neutrophils. While healthy control neutrophils incubated with GM-CSF became primed to produce ROS in response to stimulation with fMLP and phorbol-12-myristate-12-acetate (PMA), RA neutrophils produced increased levels of ROS without the need for priming. JAKi prevented ROS release from primed healthy control neutrophils in response to fMLP, but had no effect on ROS production by RA neutrophils. Baricitinib reversed GM-CSF priming of ROS production in response to fMLP in healthy control, but not RA, neutrophils. We conclude that incubation with JAKi prevents chemotaxis of RA neutrophils towards IL-8, but does not prevent the production of ROS or increase the level of apoptosis. This may be due to the in-vivo exposure of RA neutrophils to priming agents other than those that activate JAK/signal transducer and activator of transcription (STAT) signalling., (© 2017 British Society for Immunology.)
- Published
- 2017
- Full Text
- View/download PDF
43. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
- Author
-
Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, Pease CT, Price EJ, Sutcliffe N, Gendi NST, Hall FC, Ruddock SP, Fernandez C, Reynolds C, Hulme CT, Davies KA, Edwards CJ, Lanyon PC, Moots RJ, Roussou E, Giles IP, Sharples LD, and Bombardieri M
- Subjects
- Adult, Aged, Antirheumatic Agents economics, Cost-Benefit Analysis, Double-Blind Method, Fatigue etiology, Female, Humans, Male, Middle Aged, Odds Ratio, Patient Reported Outcome Measures, Quality of Life, Quality-Adjusted Life Years, Rituximab economics, Sjogren's Syndrome complications, Treatment Outcome, United Kingdom, Visual Analog Scale, Xerostomia etiology, Antirheumatic Agents therapeutic use, Fatigue drug therapy, Rituximab therapeutic use, Sjogren's Syndrome drug therapy, Xerostomia drug therapy
- Abstract
Objective: To investigate whether rituximab, an anti-B cell therapy, improves symptoms of fatigue and oral dryness in patients with primary Sjögren's syndrome (SS)., Methods: We conducted a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that included health economic analysis. Anti-Ro-positive patients with primary SS, symptomatic fatigue, and oral dryness were recruited from 25 UK rheumatology clinics from August 2011 to January 2014. Patients were centrally randomized to receive either intravenous (IV) placebo (250 ml saline) or IV rituximab (1,000 mg in 250 ml saline) in 2 courses at weeks 0, 2, 24, and 26, with pre- and postinfusion medication including corticosteroids. The primary end point was the proportion of patients achieving a 30% reduction in either fatigue or oral dryness at 48 weeks, as measured by visual analog scale. Other outcome measures included salivary and lacrimal flow rates, quality of life, scores on the European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index and EULAR Sjögren's Syndrome Disease Activity Index, symptoms of ocular and overall dryness, pain, globally assessed disease activity, and cost-effectiveness., Results: All 133 patients who were randomized to receive placebo (n = 66) or rituximab (n = 67) were included in the primary analysis. Among patients with complete data, 21 of 56 placebo-treated patients and 24 of 61 rituximab-treated patients achieved the primary end point. After multiple imputation of missing outcomes, response rates in the placebo and rituximab groups were 36.8% and 39.8%, respectively (adjusted odds ratio 1.13 [95% confidence interval 0.50, 2.55]). There were no significant improvements in any outcome measure except for unstimulated salivary flow. The mean ± SD costs per patient for rituximab and placebo were £10,752 ± 264.75 and £2,672 ± 241.71, respectively. There were slightly more adverse events (AEs) reported in total for rituximab, but there was no difference in serious AEs (10 in each group)., Conclusion: The results of this study indicate that rituximab is neither clinically effective nor cost-effective in this patient population., (© 2017, American College of Rheumatology.)
- Published
- 2017
- Full Text
- View/download PDF
44. Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
- Author
-
Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, and Vlahos B
- Abstract
[This corrects the article DOI: 10.1371/journal.pone.0175207.].
- Published
- 2017
- Full Text
- View/download PDF
45. Fibromyalgia in Behçet's disease: a narrative review.
- Author
-
Jobanputra C, Richey RH, Nair J, Moots RJ, and Goebel A
- Abstract
Introduction: Fibromyalgia is characterised by chronic widespread pain and tenderness. It has often been reported to occur concomitantly with chronic rheumatological conditions. Behçet's disease is a chronic relapsing, multisystem, autoinflammatory disease. There is only limited understanding of a potential relationship between fibromyalgia and Behçet's disease., Aim: Given the potential detrimental influence of pain on the outcome of chronic disease, the aim of this narrative review is to gain an understanding of the incidence and presentation of fibromyalgia in Behçet's disease., Methods: Electronic databases Scopus, Medline, PubMed and UpToDate were searched., Results: A total of 269 studies were identified, and limitations and exclusion/inclusion criteria were applied to ensure accurate and comparable selection of studies; four studies were selected. All cases were assessed for the presence of fibromyalgia according to the 1990 or 2010 diagnostic criteria of the American College of Rheumatology, with Behçet's disease diagnosed according to the International Study Group (ISG) for Behçet's disease criteria. A higher prevalence of fibromyalgia (5.7-37.1%) was reported in Behçet's disease compared to that of the general population (2.9-4.7%)., Discussion: While an increased prevalence of fibromyalgia was found in patients with Behçet's disease, this needs to be considered within the context of limited available evidence. The potential impact of these conditions on the disease activity of each other is not clear and may require a prospective study., Conclusion: Fibromyalgia appears to be more prevalent in those with Behçet's disease than would be expected in the overall population. Significance: This review provides some evidence that fibromyalgia is more prevalent in those with Behçet's disease. To ensure appropriate patient treatment choices, it is important that both conditions are diagnosed where they co-exist., Competing Interests: Conflict of interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
- Published
- 2017
- Full Text
- View/download PDF
46. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
- Author
-
Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, and Vlahos B
- Subjects
- Adalimumab adverse effects, Adalimumab immunology, Adalimumab pharmacology, Adalimumab therapeutic use, Antirheumatic Agents therapeutic use, Dose-Response Relationship, Drug, Etanercept adverse effects, Etanercept immunology, Etanercept pharmacology, Etanercept therapeutic use, Female, Humans, Infliximab adverse effects, Infliximab immunology, Infliximab pharmacology, Infliximab therapeutic use, Internationality, Male, Middle Aged, Safety, Antibodies immunology, Antirheumatic Agents immunology, Antirheumatic Agents pharmacology, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid immunology
- Abstract
Objective: To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough drug concentration, efficacy, and patient-reported outcomes., Methods: This multi-national, non-interventional, cross-sectional study (NCT01981473) enrolled adult patients with RA treated continuously for 6-24 months with ETN, ADL, or IFX. ADA and trough drug concentrations were measured by independent assays ≤2 days before the next scheduled dose. Efficacy measurements included Disease Activity Score 28-joint count (DAS28), low disease activity (LDA), remission, and erythrocyte sedimentation rate (ESR). Targeted medical histories of injection site/infusion reactions, serum sickness, and thromboembolic events were collected., Results: Baseline demographics of the 595 patients (ETN: n = 200; ADL: n = 199; IFX: n = 196) were similar across groups. The mean duration of treatment was 14.6, 13.5, and 13.1 months for ETN, ADL, and IFX, respectively. All ETN-treated patients tested negative for ADA, whereas 31.2% and 17.4% patients treated with ADL and IFX, respectively, tested positive. In ADL- or IFX-treated patients, those with ADA had significantly lower trough drug concentrations. There were negative correlations between trough drug levels and both CRP and ESR in ADL- and IFX-treated patients. DAS28-ESR LDA and remission rates were higher in patients without ADA. The rate of targeted medical events reported was low., Conclusion: ADA were detected in ADL- and IFX-treated but not ETN-treated patients. Patients without ADA generally showed numerically better clinical outcomes than those with ADA., Trial Registration: This study was registered on www.ClinicalTrials.gov (NCT01981473).
- Published
- 2017
- Full Text
- View/download PDF
47. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.
- Author
-
Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F, Dimonaco S, Rubbert-Roth A, van Vollenhoven R, and Genovese MC
- Subjects
- Clinical Trials, Phase III as Topic, Clinical Trials, Phase IV as Topic, Double-Blind Method, Female, Humans, Leukocyte Count, Male, Middle Aged, Neutrophil Activation drug effects, Opportunistic Infections etiology, Randomized Controlled Trials as Topic, Antibodies, Monoclonal, Humanized therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Neutrophils drug effects
- Abstract
Objectives: To investigate changes in neutrophil count and occurrences of infection in RA patients treated with the IL-6 receptor-α inhibitor tocilizumab (TCZ)., Methods: Data were pooled from patients who received i.v. TCZ (4 mg/kg + MTX, 8 mg/kg ± DMARDs, 10 mg/kg) or placebo + DMARDs in phase 3/4 clinical trials, long-term extensions or a pharmacology study. Neutrophil counts were measured routinely according to the Common Toxicity Criteria for Adverse Events grades; TCZ dosing was adjusted if necessary. Covariates associated with decreased neutrophil counts were assessed with multivariate regression analysis. Infection rates within 30 days of neutrophil count changes were calculated per 100 patient-years of TCZ exposure., Results: In placebo-controlled parts of trials, more TCZ-treated than placebo-treated patients had grade 1/2 or 3/4 neutrophil counts (TCZ: 28.2%/3.1%; placebo: 8.9%/0.2%). In placebo-controlled trials + long-term extensions, 4171 patients provided 16204.8 patient-years of TCZ exposure. Neutrophil counts decreased through week 6 from baseline [mean ( s . d .) change, -2.17 (2.16) × 10 9 /l) and remained stable thereafter. Rates (95% CI) of serious infections within 30 days of normal [4.66 (4.31, 5.03)], grade 1/2 [2.48 (1.79, 3.34)] and 3/4 [2.77 (0.34, 10.01)] neutrophil counts were similar. Baseline neutrophil count <2 × 10 9 /l and female gender were associated with grade 3/4 neutrophil counts [odds ratio (OR) (95% CI): 19.02 (6.76, 53.52), 2.55 (1.40, 4.66)]. Patients who stopped TCZ in response to decreased neutrophil count returned more quickly to normal levels than patients who reduced or continued their dose., Conclusion: Decreases in neutrophil counts in patients taking TCZ do not appear to be associated with serious infections and are normalized by current risk mitigation guidelines., (© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2017
- Full Text
- View/download PDF
48. Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis.
- Author
-
Wright HL, Cox T, Moots RJ, and Edwards SW
- Subjects
- Arthritis, Rheumatoid pathology, Cohort Studies, Gene Expression Profiling, Humans, Pancreatic Elastase metabolism, Peroxidase metabolism, ROC Curve, Reproducibility of Results, Sequence Analysis, RNA, Transcriptome genetics, Tumor Necrosis Factor-alpha metabolism, Arthritis, Rheumatoid drug therapy, Biomarkers metabolism, Neutrophils metabolism, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Neutrophils are implicated in the pathology of rheumatoid arthritis (RA), but the mechanisms regulating their activation are largely unknown. RA is a heterogeneous disease, and whereas many patients show clinical improvement during TNF inhibitor (TNFi) therapy, a significant proportion fails to respond. In vitro activation of neutrophils with agents, including TNF, results in rapid and selective changes in gene expression, but how neutrophils contribute to TNF signaling in RA and whether TNFi sensitivity involves differential neutrophil responses are unknown. With the use of RNA sequencing (RNA-Seq), we analyzed blood neutrophils from 20 RA patients, pre-TNFi therapy, to identify biomarkers of response, measured by a decrease in disease activity score based on 28 joint count (DAS28), 12 wk post-therapy. Biomarkers were validated by quantitative PCR (qPCR) of blood neutrophils from 2 further independent cohorts of RA patients: 16 pre-TNFi and 16 predisease-modifying anti-rheumatic drugs (DMARDs). Twenty-three neutrophil transcripts predicted a 12-wk response to TNFi: 10 (IFN-regulated) genes predicting a European League against Rheumatism (EULAR) good response and 13 different genes [neutrophil granule protein (NGP) genes] predicting a nonresponse. Statistical analysis indicated a predictive sensitivity and specificity of each gene in the panel of >80%, with some 100% specific. A combination of 3 genes [ cytidine monophosphate kinase 2 ( CMPK2 ), IFN-induced protein with tetratricopeptide repeats 1B ( IFIT1B ), and RNASE3 ] had the greatest predictive power [area under the curve (AUC) 0.94]. No correlation was found for a response to DMARDs. We conclude that this panel of genes is selective for predicting a response to TNFi and is not a surrogate marker for disease improvement. We also show that in RA, there is great plasticity in neutrophil phenotype, with circulating cells expressing genes normally only expressed in more immature cells., (© Society for Leukocyte Biology.)
- Published
- 2017
- Full Text
- View/download PDF
49. Low-density granulocytes: functionally distinct, immature neutrophils in rheumatoid arthritis with altered properties and defective TNF signalling.
- Author
-
Wright HL, Makki FA, Moots RJ, and Edwards SW
- Subjects
- Adult, Aged, Aged, 80 and over, Apoptosis genetics, Arthritis, Rheumatoid blood, Arthritis, Rheumatoid genetics, Cell Cycle genetics, Chemotaxis genetics, Cytokines metabolism, Extracellular Traps metabolism, Female, Gene Expression Profiling, Humans, Male, Middle Aged, Phagocytosis genetics, Reactive Oxygen Species metabolism, Receptors, Tumor Necrosis Factor metabolism, Sequence Analysis, RNA, Young Adult, Arthritis, Rheumatoid metabolism, Arthritis, Rheumatoid pathology, Neutrophils metabolism, Signal Transduction, Tumor Necrosis Factor-alpha metabolism
- Abstract
Our aim was to determine whether rheumatoid arthritis (RA) low-density granulocytes (LDGs) are functionally different from RA neutrophils. LDGs from 32 RA patients were characterized using flow cytometry and quantitative PCR (qPCR). RNA sequencing (RNA-Seq) was carried out on paired RA LDGs and neutrophils (n = 4) and validated using qPCR. Functional assays included chemotaxis, phagocytosis, reactive oxygen species (ROS) production, cell-cycle analysis, apoptosis, neutrophil extracellular trap (NET)osis, and measurement of cytokine production (n ≥ 5 paired RA LDGs/neutrophils). RA LDGs had a substantially altered transcriptome, expressing >5000 genes at significantly different levels compared with RA neutrophils, including elevated levels of transcripts for granule proteins [including elastase and myeloperoxidase (MPO)] and cell-cycle genes [including cyclin-dependent kinase (CDK)2, CDK4, and CDK6]. Approximately 1% of RA LDGs stained positive for the G2/S phase of the cell cycle. RA LDGs had a significantly lower constitutive rate of apoptosis compared with RA neutrophils and did not respond to TNF-α in culture. Expression of transcripts for cytokines and cytokine receptors was lower in RA LDGs. NET formation was lower in LDGs in response to PMA compared with RA neutrophils. Chemotaxis and phagocytosis was lower in RA LDGs compared with neutrophils. RA LDGs produced significantly lower amounts of ROS in response to fMLP following priming with TNF-α. Expression of TNFR1 and -2 mRNA and protein was significantly lower in LDGs. We conclude that RA LDGS are functionally different from RA neutrophils, representing an immature neutrophil population within peripheral blood. Their enhanced survival properties and decreased TNF signaling are likely to have important consequences for disease pathology and response to therapy., (© Society for Leukocyte Biology.)
- Published
- 2017
- Full Text
- View/download PDF
50. Behcet's disease.
- Author
-
Nair JR and Moots RJ
- Subjects
- Humans, Behcet Syndrome
- Abstract
Behçet's disease (BD) is a chronic relapsing and remitting vasculitis of unknown aetiology. It has the capacity to affect almost all organ systems because of its potential to involve both arteries and veins of all sizes, resulting in significant organ-threatening morbidity and mortality. Traditionally known as the 'silk road' disease, it has a worldwide occurrence. The aetiopathological mechanisms of disease development in BD remain poorly understood, but genome wide studies show human leukocyte antigen and non-human leukocyte antigen associations. Environmental influences and genetic factors may have a role in the aetiopathogenetic mechanisms that lead to development of the disease, indicating the autoimmune and auto-inflammatory nature of BD. The evidence base for treatment is limited but new knowledge is emerging and current treatment options range from symptomatic treatment, through to non-biological and biological immunosuppressive drugs, to cover the spectrum of clinical manifestations., (© Royal College of Physicians 2017. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.